At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 330 enrolled
Drug / intervention
AL-SENSE Diagnostic Absorbent Panty liner +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pivotal Study of the Al-ASense Study Protocol
In Brief
A Phase 2 clinical trial evaluating AL-SENSE Diagnostic Absorbent Panty liner for Amniotic Fluid Leakage. Completed, enrolled 330 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this study is to demonstrate that the Diagnostic Absorbent Panty liner (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd., can distinguish between wetness sensed by pregnant women that is caused by amniotic fluid leakage and that which is caused by urinary incontinence.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmniotic Fluid Leakage
CountriesIsrael, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
Primary CompletionNov 2006
First PostedJan 2008
TodayJul 2026
First PostedJan 30, 2008
Enrollment StartMay 1, 2006
Primary CompletionNov 1, 2006
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 18.4 years ago
Interventions
AL-SENSE Diagnostic Absorbent Panty linerdevice
worn for 12 hours
AL-SENSE Diagnostic Absorbent Panty linerdevice
Diagnostic Absorbent Panty liner (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd worn for 12 hours